In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus

Hung Jen Tang, Chi Chung Chen, Chih Cheng Lai, Chun Cheng Zhang, Tzu Chieh Weng, Yu Hsin Chiu, Han Siong Toh, Shyh Ren Chiang, Wen Liang Yu, Wen Chien Ko, Yin Ching Chuang

研究成果: 雜誌貢獻文章

4 引文 (Scopus)

摘要

Background/purpose: The aim of this study is to investigate the role of tigecycline in Vibrio vulnificus infection. Methods: Eight randomly selected clinical V. vulnificus isolates were studied to obtain the minimal inhibitory concentrations (MICs) of minocycline, cefotaxime, and tigecycline, and the time-kill curves of tigecycline alone or in combination with other drugs. A peritonitis mouse model was used for the evaluation of the therapeutic efficacy of tigecycline alone or cefotaxime in combination with minocycline or tigecycline. Results: The MIC of minocycline, cefotaxime, and tigecycline for eight clinical V. vulnificus isolates was 0.06-0.12 μg/mL, 0.03-0.06 μg/mL, and 0.03-0.06 μg/mL, respectively. In time-killing studies, at the concentration of 1 × MIC, the inhibitory effect of tigecycline persisted for 24 hours in five of eight isolates. With 2 × MIC and trough level, the inhibitory effect was noted in all isolates for 24 hours. With the combination of minocycline plus cefotaxime and tigecycline plus cefotaxime at 1/2 × MIC, the bactericidal effect was noted in 25% and 62.5% of eight isolates and synergism in 50% and 75% of isolates. With a low (1.25 × 105 CFU/mL) inoculum, all infected mice survived with tigecycline alone, tigecycline plus cefotaxime, or minocycline plus cefotaxime on the 14th day. At the inoculum of 1.25 × 106 CFU, the survival rate was 33.3% on the 14th day in the tigecycline plus cefotaxime-treated group, but none of the mice treated by tigecycline alone or minocycline plus cefotaxime survived (33.3% vs. 0%, p = 0.01 by Fisher's exact test). Conclusion: Our in vitro combination and animal studies indicate that tigecycline could be an option for the treatment of invasive V. vulnificus infections.

原文英語
頁(從 - 到)76-81
期刊Journal of Microbiology, Immunology and Infection
51
發行號1
DOIs
出版狀態已發佈 - 二月 1 2018
對外發佈Yes

指紋

Vibrio vulnificus
Cefotaxime
Minocycline
tigecycline
In Vitro Techniques
Peritonitis

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology and Allergy
  • Immunology and Microbiology(all)
  • Infectious Diseases

引用此文

Tang, H. J., Chen, C. C., Lai, C. C., Zhang, C. C., Weng, T. C., Chiu, Y. H., ... Chuang, Y. C. (2018). In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus. Journal of Microbiology, Immunology and Infection, 51(1), 76-81. https://doi.org/10.1016/j.jmii.2016.04.009

In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus. / Tang, Hung Jen; Chen, Chi Chung; Lai, Chih Cheng; Zhang, Chun Cheng; Weng, Tzu Chieh; Chiu, Yu Hsin; Toh, Han Siong; Chiang, Shyh Ren; Yu, Wen Liang; Ko, Wen Chien; Chuang, Yin Ching.

於: Journal of Microbiology, Immunology and Infection, 卷 51, 編號 1, 01.02.2018, p. 76-81.

研究成果: 雜誌貢獻文章

Tang, HJ, Chen, CC, Lai, CC, Zhang, CC, Weng, TC, Chiu, YH, Toh, HS, Chiang, SR, Yu, WL, Ko, WC & Chuang, YC 2018, 'In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus', Journal of Microbiology, Immunology and Infection, 卷 51, 編號 1, 頁 76-81. https://doi.org/10.1016/j.jmii.2016.04.009
Tang, Hung Jen ; Chen, Chi Chung ; Lai, Chih Cheng ; Zhang, Chun Cheng ; Weng, Tzu Chieh ; Chiu, Yu Hsin ; Toh, Han Siong ; Chiang, Shyh Ren ; Yu, Wen Liang ; Ko, Wen Chien ; Chuang, Yin Ching. / In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus. 於: Journal of Microbiology, Immunology and Infection. 2018 ; 卷 51, 編號 1. 頁 76-81.
@article{5608722925d54461bd946c1ad2178d5d,
title = "In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus",
abstract = "Background/purpose: The aim of this study is to investigate the role of tigecycline in Vibrio vulnificus infection. Methods: Eight randomly selected clinical V. vulnificus isolates were studied to obtain the minimal inhibitory concentrations (MICs) of minocycline, cefotaxime, and tigecycline, and the time-kill curves of tigecycline alone or in combination with other drugs. A peritonitis mouse model was used for the evaluation of the therapeutic efficacy of tigecycline alone or cefotaxime in combination with minocycline or tigecycline. Results: The MIC of minocycline, cefotaxime, and tigecycline for eight clinical V. vulnificus isolates was 0.06-0.12 μg/mL, 0.03-0.06 μg/mL, and 0.03-0.06 μg/mL, respectively. In time-killing studies, at the concentration of 1 × MIC, the inhibitory effect of tigecycline persisted for 24 hours in five of eight isolates. With 2 × MIC and trough level, the inhibitory effect was noted in all isolates for 24 hours. With the combination of minocycline plus cefotaxime and tigecycline plus cefotaxime at 1/2 × MIC, the bactericidal effect was noted in 25{\%} and 62.5{\%} of eight isolates and synergism in 50{\%} and 75{\%} of isolates. With a low (1.25 × 105 CFU/mL) inoculum, all infected mice survived with tigecycline alone, tigecycline plus cefotaxime, or minocycline plus cefotaxime on the 14th day. At the inoculum of 1.25 × 106 CFU, the survival rate was 33.3{\%} on the 14th day in the tigecycline plus cefotaxime-treated group, but none of the mice treated by tigecycline alone or minocycline plus cefotaxime survived (33.3{\%} vs. 0{\%}, p = 0.01 by Fisher's exact test). Conclusion: Our in vitro combination and animal studies indicate that tigecycline could be an option for the treatment of invasive V. vulnificus infections.",
keywords = "Killing effects, Tigecycline, Vibrio vulnificus",
author = "Tang, {Hung Jen} and Chen, {Chi Chung} and Lai, {Chih Cheng} and Zhang, {Chun Cheng} and Weng, {Tzu Chieh} and Chiu, {Yu Hsin} and Toh, {Han Siong} and Chiang, {Shyh Ren} and Yu, {Wen Liang} and Ko, {Wen Chien} and Chuang, {Yin Ching}",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.jmii.2016.04.009",
language = "English",
volume = "51",
pages = "76--81",
journal = "Journal of Microbiology, Immunology and Infection",
issn = "0253-2662",
publisher = "Elsevier Taiwan LLC",
number = "1",

}

TY - JOUR

T1 - In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus

AU - Tang, Hung Jen

AU - Chen, Chi Chung

AU - Lai, Chih Cheng

AU - Zhang, Chun Cheng

AU - Weng, Tzu Chieh

AU - Chiu, Yu Hsin

AU - Toh, Han Siong

AU - Chiang, Shyh Ren

AU - Yu, Wen Liang

AU - Ko, Wen Chien

AU - Chuang, Yin Ching

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Background/purpose: The aim of this study is to investigate the role of tigecycline in Vibrio vulnificus infection. Methods: Eight randomly selected clinical V. vulnificus isolates were studied to obtain the minimal inhibitory concentrations (MICs) of minocycline, cefotaxime, and tigecycline, and the time-kill curves of tigecycline alone or in combination with other drugs. A peritonitis mouse model was used for the evaluation of the therapeutic efficacy of tigecycline alone or cefotaxime in combination with minocycline or tigecycline. Results: The MIC of minocycline, cefotaxime, and tigecycline for eight clinical V. vulnificus isolates was 0.06-0.12 μg/mL, 0.03-0.06 μg/mL, and 0.03-0.06 μg/mL, respectively. In time-killing studies, at the concentration of 1 × MIC, the inhibitory effect of tigecycline persisted for 24 hours in five of eight isolates. With 2 × MIC and trough level, the inhibitory effect was noted in all isolates for 24 hours. With the combination of minocycline plus cefotaxime and tigecycline plus cefotaxime at 1/2 × MIC, the bactericidal effect was noted in 25% and 62.5% of eight isolates and synergism in 50% and 75% of isolates. With a low (1.25 × 105 CFU/mL) inoculum, all infected mice survived with tigecycline alone, tigecycline plus cefotaxime, or minocycline plus cefotaxime on the 14th day. At the inoculum of 1.25 × 106 CFU, the survival rate was 33.3% on the 14th day in the tigecycline plus cefotaxime-treated group, but none of the mice treated by tigecycline alone or minocycline plus cefotaxime survived (33.3% vs. 0%, p = 0.01 by Fisher's exact test). Conclusion: Our in vitro combination and animal studies indicate that tigecycline could be an option for the treatment of invasive V. vulnificus infections.

AB - Background/purpose: The aim of this study is to investigate the role of tigecycline in Vibrio vulnificus infection. Methods: Eight randomly selected clinical V. vulnificus isolates were studied to obtain the minimal inhibitory concentrations (MICs) of minocycline, cefotaxime, and tigecycline, and the time-kill curves of tigecycline alone or in combination with other drugs. A peritonitis mouse model was used for the evaluation of the therapeutic efficacy of tigecycline alone or cefotaxime in combination with minocycline or tigecycline. Results: The MIC of minocycline, cefotaxime, and tigecycline for eight clinical V. vulnificus isolates was 0.06-0.12 μg/mL, 0.03-0.06 μg/mL, and 0.03-0.06 μg/mL, respectively. In time-killing studies, at the concentration of 1 × MIC, the inhibitory effect of tigecycline persisted for 24 hours in five of eight isolates. With 2 × MIC and trough level, the inhibitory effect was noted in all isolates for 24 hours. With the combination of minocycline plus cefotaxime and tigecycline plus cefotaxime at 1/2 × MIC, the bactericidal effect was noted in 25% and 62.5% of eight isolates and synergism in 50% and 75% of isolates. With a low (1.25 × 105 CFU/mL) inoculum, all infected mice survived with tigecycline alone, tigecycline plus cefotaxime, or minocycline plus cefotaxime on the 14th day. At the inoculum of 1.25 × 106 CFU, the survival rate was 33.3% on the 14th day in the tigecycline plus cefotaxime-treated group, but none of the mice treated by tigecycline alone or minocycline plus cefotaxime survived (33.3% vs. 0%, p = 0.01 by Fisher's exact test). Conclusion: Our in vitro combination and animal studies indicate that tigecycline could be an option for the treatment of invasive V. vulnificus infections.

KW - Killing effects

KW - Tigecycline

KW - Vibrio vulnificus

UR - http://www.scopus.com/inward/record.url?scp=84973562876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973562876&partnerID=8YFLogxK

U2 - 10.1016/j.jmii.2016.04.009

DO - 10.1016/j.jmii.2016.04.009

M3 - Article

AN - SCOPUS:84973562876

VL - 51

SP - 76

EP - 81

JO - Journal of Microbiology, Immunology and Infection

JF - Journal of Microbiology, Immunology and Infection

SN - 0253-2662

IS - 1

ER -